Is PIII or LFMD more profitable?

LifeMD has a net margin of 2.37% compared to P3 Health Partners' net margin of -8.57%. LifeMD's return on equity of -150.88% beat P3 Health Partners' return on equity. Company Net Margins Return on Equity Return on Assets P3 Health Partners -8.57% -302.33% -19.99% LifeMD 2.37% -150.88% -22.59%

Does the media prefer PIII or LFMD?

In the previous week, LifeMD had 2 more articles in the media than P3 Health Partners. MarketBeat recorded 3 mentions for LifeMD and 1 mentions for P3 Health Partners. P3 Health Partners' average media sentiment score of 0.59 beat LifeMD's score of 0.21 indicating that P3 Health Partners is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment P3 Health Partners 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LifeMD 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PIII or BDSX more profitable?

P3 Health Partners has a net margin of -8.57% compared to Biodesix's net margin of -33.26%. P3 Health Partners' return on equity of -302.33% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets P3 Health Partners -8.57% -302.33% -19.99% Biodesix -33.26% -2,101.40% -35.65%

Is XGN or PIII more profitable?

P3 Health Partners has a net margin of -8.57% compared to Exagen's net margin of -29.49%. Exagen's return on equity of -94.37% beat P3 Health Partners' return on equity. Company Net Margins Return on Equity Return on Assets Exagen -29.49% -94.37% -28.96% P3 Health Partners -8.57% -302.33% -19.99%

Does the media favor XGN or PIII?

In the previous week, Exagen and Exagen both had 1 articles in the media. P3 Health Partners' average media sentiment score of 0.59 beat Exagen's score of 0.00 indicating that P3 Health Partners is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exagen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral P3 Health Partners 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate BNR or PIII?

P3 Health Partners has a consensus target price of $14.00, indicating a potential upside of 25.29%. Given P3 Health Partners' stronger consensus rating and higher probable upside, analysts clearly believe P3 Health Partners is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 P3 Health Partners 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

P3 Health Partners (PIII) Competitors

$11.24 -0.75 (-6.21%)

As of 02:27 PM Eastern

Compare

PIII vs. SBC, LFMD, BDSX, XGN, and BNR

Should you buy P3 Health Partners stock or one of its competitors? MarketBeat compares P3 Health Partners with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with P3 Health Partners include SBC Medical Group (SBC), LifeMD (LFMD), Biodesix (BDSX), Exagen (XGN), and Burning Rock Biotech (BNR). These companies are all part of the "healthcare" industry.

How does P3 Health Partners compare to SBC Medical Group?

P3 Health Partners (NASDAQ:PIII) and SBC Medical Group (NASDAQ:SBC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

7.8% of P3 Health Partners shares are held by institutional investors. Comparatively, 60.8% of SBC Medical Group shares are held by institutional investors. 10.9% of P3 Health Partners shares are held by company insiders. Comparatively, 81.7% of SBC Medical Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

SBC Medical Group has lower revenue, but higher earnings than P3 Health Partners. P3 Health Partners is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
P3 Health Partners	$1.47B	0.05	-$147.95M	-$38.60	N/A
SBC Medical Group	$169.34M	1.90	$50.99M	$0.39	8.04

P3 Health Partners presently has a consensus target price of $14.00, suggesting a potential upside of 25.29%. SBC Medical Group has a consensus target price of $8.50, suggesting a potential upside of 171.13%. Given SBC Medical Group's stronger consensus rating and higher probable upside, analysts clearly believe SBC Medical Group is more favorable than P3 Health Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SBC Medical Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

SBC Medical Group has a net margin of 24.09% compared to P3 Health Partners' net margin of -8.57%. SBC Medical Group's return on equity of 15.90% beat P3 Health Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
P3 Health Partners	-8.57%	-302.33%	-19.99%
SBC Medical Group	24.09%	15.90%	11.61%

P3 Health Partners has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market. Comparatively, SBC Medical Group has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

In the previous week, P3 Health Partners had 1 more articles in the media than SBC Medical Group. MarketBeat recorded 1 mentions for P3 Health Partners and 0 mentions for SBC Medical Group. P3 Health Partners' average media sentiment score of 0.59 beat SBC Medical Group's score of 0.00 indicating that P3 Health Partners is being referred to more favorably in the media.

Company	Overall Sentiment
P3 Health Partners	Positive
SBC Medical Group	Neutral

Summary

SBC Medical Group beats P3 Health Partners on 12 of the 16 factors compared between the two stocks.

How does P3 Health Partners compare to LifeMD?

P3 Health Partners (NASDAQ:PIII) and LifeMD (NASDAQ:LFMD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

LifeMD has a net margin of 2.37% compared to P3 Health Partners' net margin of -8.57%. LifeMD's return on equity of -150.88% beat P3 Health Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
P3 Health Partners	-8.57%	-302.33%	-19.99%
LifeMD	2.37%	-150.88%	-22.59%

P3 Health Partners has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market. Comparatively, LifeMD has a beta of 1.98, meaning that its stock price is 98% more volatile than the broader market.

In the previous week, LifeMD had 2 more articles in the media than P3 Health Partners. MarketBeat recorded 3 mentions for LifeMD and 1 mentions for P3 Health Partners. P3 Health Partners' average media sentiment score of 0.59 beat LifeMD's score of 0.21 indicating that P3 Health Partners is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
P3 Health Partners	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LifeMD	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

P3 Health Partners presently has a consensus price target of $14.00, indicating a potential upside of 25.29%. LifeMD has a consensus price target of $9.14, indicating a potential upside of 106.81%. Given LifeMD's stronger consensus rating and higher possible upside, analysts plainly believe LifeMD is more favorable than P3 Health Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

LifeMD has lower revenue, but higher earnings than P3 Health Partners. P3 Health Partners is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
P3 Health Partners	$1.47B	0.05	-$147.95M	-$38.60	N/A
LifeMD	$193.33M	1.11	$14.35M	$0.05	88.42

7.8% of P3 Health Partners shares are owned by institutional investors. Comparatively, 35.5% of LifeMD shares are owned by institutional investors. 10.9% of P3 Health Partners shares are owned by insiders. Comparatively, 17.2% of LifeMD shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

LifeMD beats P3 Health Partners on 13 of the 16 factors compared between the two stocks.

How does P3 Health Partners compare to Biodesix?

P3 Health Partners (NASDAQ:PIII) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

Biodesix has lower revenue, but higher earnings than P3 Health Partners. Biodesix is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
P3 Health Partners	$1.47B	0.05	-$147.95M	-$38.60	N/A
Biodesix	$96.10M	2.13	-$35.26M	-$4.06	N/A

7.8% of P3 Health Partners shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 10.9% of P3 Health Partners shares are owned by company insiders. Comparatively, 23.2% of Biodesix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

P3 Health Partners has a net margin of -8.57% compared to Biodesix's net margin of -33.26%. P3 Health Partners' return on equity of -302.33% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
P3 Health Partners	-8.57%	-302.33%	-19.99%
Biodesix	-33.26%	-2,101.40%	-35.65%

P3 Health Partners has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market. Comparatively, Biodesix has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

In the previous week, P3 Health Partners and P3 Health Partners both had 1 articles in the media. Biodesix's average media sentiment score of 1.34 beat P3 Health Partners' score of 0.59 indicating that Biodesix is being referred to more favorably in the news media.

Company	Overall Sentiment
P3 Health Partners	Positive
Biodesix	Positive

P3 Health Partners presently has a consensus price target of $14.00, indicating a potential upside of 25.29%. Biodesix has a consensus price target of $26.50, indicating a potential upside of 34.14%. Given Biodesix's stronger consensus rating and higher possible upside, analysts clearly believe Biodesix is more favorable than P3 Health Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Biodesix beats P3 Health Partners on 9 of the 15 factors compared between the two stocks.

How does P3 Health Partners compare to Exagen?

Exagen (NASDAQ:XGN) and P3 Health Partners (NASDAQ:PIII) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Exagen has higher earnings, but lower revenue than P3 Health Partners. Exagen is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$68.38M	1.58	-$19.95M	-$0.89	N/A
P3 Health Partners	$1.47B	0.05	-$147.95M	-$38.60	N/A

Exagen currently has a consensus target price of $9.25, suggesting a potential upside of 106.24%. P3 Health Partners has a consensus target price of $14.00, suggesting a potential upside of 25.29%. Given Exagen's stronger consensus rating and higher probable upside, analysts plainly believe Exagen is more favorable than P3 Health Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

P3 Health Partners has a net margin of -8.57% compared to Exagen's net margin of -29.49%. Exagen's return on equity of -94.37% beat P3 Health Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-29.49%	-94.37%	-28.96%
P3 Health Partners	-8.57%	-302.33%	-19.99%

In the previous week, Exagen and Exagen both had 1 articles in the media. P3 Health Partners' average media sentiment score of 0.59 beat Exagen's score of 0.00 indicating that P3 Health Partners is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
P3 Health Partners	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

75.3% of Exagen shares are held by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are held by institutional investors. 10.4% of Exagen shares are held by insiders. Comparatively, 10.9% of P3 Health Partners shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Exagen has a beta of 2.01, meaning that its share price is 101% more volatile than the broader market. Comparatively, P3 Health Partners has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market.

Summary

Exagen beats P3 Health Partners on 9 of the 15 factors compared between the two stocks.

How does P3 Health Partners compare to Burning Rock Biotech?

Burning Rock Biotech (NASDAQ:BNR) and P3 Health Partners (NASDAQ:PIII) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by insiders. Comparatively, 10.9% of P3 Health Partners shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Burning Rock Biotech has higher earnings, but lower revenue than P3 Health Partners. Burning Rock Biotech is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	1.12	-$7.92M	-$0.82	N/A
P3 Health Partners	$1.47B	0.05	-$147.95M	-$38.60	N/A

P3 Health Partners has a consensus target price of $14.00, indicating a potential upside of 25.29%. Given P3 Health Partners' stronger consensus rating and higher probable upside, analysts clearly believe P3 Health Partners is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Burning Rock Biotech has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Comparatively, P3 Health Partners has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market.

In the previous week, P3 Health Partners had 1 more articles in the media than Burning Rock Biotech. MarketBeat recorded 1 mentions for P3 Health Partners and 0 mentions for Burning Rock Biotech. P3 Health Partners' average media sentiment score of 0.59 beat Burning Rock Biotech's score of 0.00 indicating that P3 Health Partners is being referred to more favorably in the news media.

Company	Overall Sentiment
Burning Rock Biotech	Neutral
P3 Health Partners	Positive

P3 Health Partners has a net margin of -8.57% compared to Burning Rock Biotech's net margin of -11.57%. Burning Rock Biotech's return on equity of -10.98% beat P3 Health Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-11.57%	-10.98%	-7.33%
P3 Health Partners	-8.57%	-302.33%	-19.99%

Summary

P3 Health Partners beats Burning Rock Biotech on 9 of the 16 factors compared between the two stocks.

Get P3 Health Partners News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PIII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PIII vs. The Competition

Export

Metric	P3 Health Partners	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$80.96M	$1.62B	$6.56B	$12.14B
Dividend Yield	N/A	N/A	2.69%	5.82%
P/E Ratio	-0.29	78.52	25.23	24.15
Price / Sales	0.05	28.38	555.61	121.24
Price / Cash	N/A	23.50	44.82	54.51
Price / Book	-0.52	5.26	10.83	6.51
Net Income	-$147.95M	-$54.76M	$3.56B	$337.14M
7 Day Performance	-0.50%	0.24%	1.97%	0.16%
1 Month Performance	-15.35%	-2.53%	1.40%	1.14%
1 Year Performance	85.31%	-2.31%	31.18%	28.72%

P3 Health Partners Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PIII P3 Health Partners	2.8706 of 5 stars	$11.25 -6.2%	$14.00 +24.5%	+94.3%	$81.47M	$1.47B	N/A	500
SBC SBC Medical Group	3.0593 of 5 stars	$2.99 +2.7%	$8.50 +184.3%	-29.3%	$298.50M	$173.61M	7.67	N/A	Positive News
LFMD LifeMD	2.9911 of 5 stars	$4.82 -1.8%	$9.14 +89.7%	-68.2%	$237.46M	$194.05M	96.42	230	News Coverage Positive News
BDSX Biodesix	4.1012 of 5 stars	$15.33 -1.7%	$24.00 +56.6%	+254.8%	$161.55M	$88.50M	N/A	220	Positive News
XGN Exagen	2.739 of 5 stars	$4.55 -0.4%	$9.25 +103.3%	-37.4%	$110.41M	$66.57M	N/A	220

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PIII) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

P3 Health Partners (PIII) Competitors

PIII vs. SBC, LFMD, BDSX, XGN, and BNR

How does P3 Health Partners compare to SBC Medical Group?

Summary

How does P3 Health Partners compare to LifeMD?

Summary

How does P3 Health Partners compare to Biodesix?

Summary

How does P3 Health Partners compare to Exagen?

Summary

How does P3 Health Partners compare to Burning Rock Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PIII vs. The Competition

P3 Health Partners Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

P3 Health Partners (PIII) Competitors

PIII vs. SBC, LFMD, BDSX, XGN, and BNR

How does P3 Health Partners compare to SBC Medical Group?

Do insiders & institutionals hold more shares of PIII or SBC?

Which has preferable earnings and valuation, PIII or SBC?

Do analysts prefer PIII or SBC?

Is PIII or SBC more profitable?

Which has more risk & volatility, PIII or SBC?

Does the media prefer PIII or SBC?

Summary

How does P3 Health Partners compare to LifeMD?

Is PIII or LFMD more profitable?

Which has more volatility and risk, PIII or LFMD?

Does the media prefer PIII or LFMD?

Do analysts recommend PIII or LFMD?

Which has higher earnings and valuation, PIII or LFMD?

Do institutionals and insiders have more ownership in PIII or LFMD?

Summary

How does P3 Health Partners compare to Biodesix?

Which has higher valuation & earnings, PIII or BDSX?

Do institutionals & insiders have more ownership in PIII or BDSX?

Is PIII or BDSX more profitable?

Which has more volatility and risk, PIII or BDSX?

Does the media prefer PIII or BDSX?

Do analysts rate PIII or BDSX?

Summary

How does P3 Health Partners compare to Exagen?

Which has stronger earnings & valuation, XGN or PIII?

Do analysts prefer XGN or PIII?

Is XGN or PIII more profitable?

Does the media favor XGN or PIII?

Do insiders and institutionals believe in XGN or PIII?

Which has more risk and volatility, XGN or PIII?

Summary

How does P3 Health Partners compare to Burning Rock Biotech?

Do insiders & institutionals have more ownership in BNR or PIII?

Which has higher valuation and earnings, BNR or PIII?

Do analysts rate BNR or PIII?

Which has more risk & volatility, BNR or PIII?

Does the media favor BNR or PIII?

Is BNR or PIII more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PIII vs. The Competition

P3 Health Partners Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools